Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Biogen logo
BiogenBIIB
——
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Alkermes logo
AlkermesALKS
——
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
——
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
——

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's available for sale securities debt securities current?
Acadia Pharmaceuticals (ACAD) reported available for sale securities debt securities current of $569.25M in Q1 2026.
How has Acadia Pharmaceuticals's available for sale securities debt securities current changed year-over-year?
Acadia Pharmaceuticals's available for sale securities debt securities current increased by 22.7% year-over-year, from $463.88M to $569.25M.
What is the long-term trend for Acadia Pharmaceuticals's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Acadia Pharmaceuticals's available for sale securities debt securities current has grown at a 16.0% compound annual growth rate (CAGR), from $305.93M to $641.99M.